SC0062 medium dose ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 66 | IgA腎症 | 1 |
66. IgA腎症
臨床試験数 : 275 / 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05687890 (ClinicalTrials.gov) | April 2023 | 9/1/2023 | A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease | A Randomized, Double Blind, Placebo Parallel Controlled, 2 Cohorts, Multicenter Phase II Study to Investigate the Safety and Efficacy of SC0062 Capsule in Patients With Chronic Kidney Disease With Albuminuria | Diabetic Kidney Disease;IgA Nephropathy | Drug: Placebo of SC0062;Drug: SC0062 low dose;Drug: SC0062 medium dose;Drug: SC0062 high dose | Biocity Biopharmaceutics Co., Ltd. | NULL | Not yet recruiting | 18 Years | 70 Years | All | 240 | Phase 2 | NULL |